Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7440688
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RO7440688 is an investigational oral small molecule inhibitor of Coagulation Factor XIa (FXIa) developed by Genentech and Roche. It is designed for the treatment and prevention of cardiovascular conditions, specifically thromboembolic disorders. By targeting Factor XIa, a protease in the intrinsic coagulation pathway, the drug aims to inhibit thrombus formation with a potentially reduced risk of bleeding compared to conventional anticoagulants that target the common pathway (such as Factor Xa or Thrombin). Clinical development has included Phase I studies evaluating the safety, tolerability, and pharmacokinetics of single ascending doses in healthy volunteers, as well as the impact of food on drug absorption.
02
Targets
Factor XIa
Beyond the preview
Go deeper on RO7440688.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7440688.